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ABSTRACT
Background: Sevelamer hydrochloride (Renagel) binds phosphate in
patients with end-stage renal disease without the use of exogenous calcium
and may reduce the progression of coronary vascular calciﬁcation. This
intervention was shown to be cost-effective in the United States. This
paper presents the Canadian adaptation.
Methods: A discrete event simulation of the long-term cardiovascular
implications of 1 year of phosphate binding in a prevalent hemodialysis
population was used to estimate the cost-effectiveness of sevelamer use in
Canada based on the demographics, comorbidities, physiological and
renal characteristics. Initial calciﬁcation score and expected changes over
1 year were derived using regression equations developed from a clinical
trial and translated to cardiovascular disease risk based on equations
developed from a long-term cohort study. Direct medical costs from a
Canadian Medicare perspective were taken from Ontario data. Ten repli-
cations of 10,000 patients over 13 years (discounting at 3%) were done for
the base case and extensive sensitivity analyses were conducted.
Results: The cardioprotective effect of sevelamer over 1 year is estimated
to prevent 10 cardiovascular events and gain 18 life-years compared with
calcium carbonate in 100 patients over a lifetime. These beneﬁts are
obtained at a net cost of CAD$2,096; an incremental cost-effectiveness
ratio of CAD$12,384 per discounted life-year gained. Sensitivity analyses
showed that the time horizon and efﬁcacy were the most important
factors.
Conclusion: The results of this study provide evidence that use of seve-
lamer in Canada would be economically sound.
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Introduction
Patients with end-stage renal disease (ESRD) are at higher risk of
cardiovascular disease [1], and evidence of the predictive value of
imaging with electron-beam tomography (EBT) has been accumu-
lating [2]. An increasingly disordered calcium and phosphate
metabolism is a major contributor to widespread extra-osseous
calciﬁcation in ESRD and this is exacerbated by the use of
calcium-based phosphate binders [3]. Sevelamer hydrochloride
(Renagel, Genzyme Corporation, Cambridge, MA) is an effective
noncalcium phosphate binder that has been shown to reduce
coronary and aortic calciﬁcation [4]. In this brief report, we
present a Canadian adaptation of a published economic model
that assesses the clinical and economic consequences of the choice
of phosphate binder [5].
Methods
The model (Fig. 1) is a discrete event simulation of the changes in
calciﬁcation score that occur over 1 year, depending on phos-
phate binder and patient characteristics. The resulting cardiovas-
cular risk and its clinical and economic sequelae are also
estimated. At the start, each patient is assigned characteristics by
sampling distributions for demographics, physiological param-
eters, including calciﬁcation score, and comorbidities. The
patient is copied to ensure only the phosphate binder differs: one
copy receives sevelamer, the other a calcium-based binder.
Changes in cardiac calciﬁcation, physiologic and renal param-
eters are derived using published regression equations [5]. The
long-term occurrence of cardiovascular disease [6], management
costs, and survival are accrued. The risk of a cardiovascular event
is modeled using regression equations developed based on the
only available longitudinal data set that includes information on
calciﬁcation and cardiovascular risk in patients with ESRD [6–8].
In addition to the EBT score, the regression equation includes
diabetes, C-reactive protein levels, diastolic blood pressure, sex,
smoking, hypertension, and total cholesterol. The likelihood of a
cardiovascular event being fatal is based on the longitudinal data
set (22% for an initial and 41% for a subsequent event), and
the speciﬁc event type is assigned based on the observed
distributions.
Only direct medical costs were considered (Table 1). Acute
hospital costs (including all accommodations; ancillary services
such as pharmacy, laboratory, imaging, radiology; diagnostic and
surgical procedures; and inpatient physician services) were esti-
mated from data obtained from the Ontario Case Costing Initia-
tive for each type of event deﬁned by International Statistical
Classiﬁcation of Diseases and Related Health Problems, 10th
Revision (ICD-10), developed for morbidity classiﬁcation in
Canada (ICD-10-CA) diagnosis codes. Unit costs for the physi-
cian services, proﬁled based on length of stay, case complexity
level, ambulance use, surgical procedure codes and disposition,
were obtained from the Ontario Physician Fee Schedule [9].
Because costs of post-discharge care for patients with ESRD
suffering a cardiovascular event were not available, only acute
inpatient costs are considered here. Nevertheless, this is explored
in sensitivity analyses. Because calcium acetate is not widely used
in Canada, the results focus on sevelamer (CAD$1.7750/g for
800 mg tabs) versus calcium carbonate (CAD$0.0472/g). A
weighted average daily cost was calculated for 40-mg tablets of
cholesterol-lowering drugs using the Ontario Drug Beneﬁt For-
mulary [10]. The characteristics of the patient population used
for the base case are summarized in Table 1.
The base-case runs for 13 years because most hemodialysis
patients have died by then. Costs and beneﬁts occurring beyond
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1 year are discounted at 3% per year. Results are based on 10
replications of 10,000 patients. Sensitivity analyses considered
sevelamer’s efﬁcacy, effect of calciﬁcation on cardiovascular risk,
cholesterol-lowering treatment practices, treatment cost, event
costs, time horizon, discount rate, patients’ age, baseline calcium,
and phosphate levels. Duration of risk reduction was explored as
well.
Results
After 1 year of sevelamer use, calciﬁcation increased in only 36%
of patients compared with 57% on calcium carbonate and cal-
ciﬁcation scores were 14% lower. In 100 patients, 5 fewer (32 vs.
37) suffered an initial cardiovascular event and 5 fewer a subse-
quent event [32 vs. 38 (Difference does not equal 5 events due to
rounding)] over their lifetime, representing a 13% reduction in
cardiovascular risk. Survival increased from 8.98 years to 9.22
years (discounted gain: 0.1777 years). The majority of the cost
was related to inpatient management of cardiovascular disease
(73% for sevelamer; 98% for calcium carbonate). One year of
sevelamer use accounted for 26% of the cost compared with less
than 1% for calcium. Statins made up the remaining 1% of the
cost in both groups. The savings of CAD$160,402 in cardiovas-
cular costs largely offsets the increased binder costs, leading to a
cost-effectiveness ratio of CAD$12,384 per discounted life-year
gained (dLYG).
Univariate sensitivity analyses (Fig. 2, Panel A) indicated that
results were very sensitive to time horizon and efﬁcacy but not to
cholesterol-lowering treatment practice, costs of hospitalizations,
inclusion of subsequent care costs, or patient characteristics. The
results of the multivariate sensitivity analyses—which indicate
the probability that sevelamer is cost-effective at different pos-
sible values of the maximum acceptable cost-effectiveness ratio
appropriate for decision-making—are summarized in Figure 2,
Panel B.
For 1 year of sevelamer treatment to yield incremental cost-
effectiveness ratios below CAD$25,000/dLYG, the reduction in
cardiovascular risk would have to persist for at least 6.6 years; for
CAD$50,000/dLYG, about 3.4 years; and for CAD$100,000/
dLYG, only 1.8 years.
Discussion
Despite uncertainty regarding the implications of coronary calci-
ﬁcation, it seems prudent to minimize it in patients with ESRD
because a major contributor may be the additional calcium load
from calcium-based phosphate binders. Use of sevelamer instead
is estimated to prevent about 10 cardiovascular events and to save
18 life-years per 100 treated patients, at a favorable cost-
effectiveness relative to calcium carbonate of under CAD$12,500/
dLYG.
There are some limitations to these estimates. The Canadian
adaptation of the sevelamer economicmodel focuses on costs. The
trial and epidemiological data supporting the key functional
relations in the model should be generally applicable, however.
The link between calciﬁcation and cardiovascular risk is based on
only one study, although it is consistent with the ﬁndings from
studies in individuals without ESRD. Moreover, coronary calciﬁ-
cation was recently demonstrated to be a signiﬁcant predictor of
all-cause mortality in subjects new to hemodialysis [11]. Although
calciﬁcation has been shown to be a strong independent predictor
of cardiovascular and all-causemortality in ESRD, it remains to be
proven that interventions that prevent calciﬁcation will actually
result in lower cardiovascular risk. This can only be shown
conclusively on the basis of long-term intervention studies that
speciﬁcally address calciﬁcation and its relation to long-term
outcomes. Although not conclusive, the initial results look prom-
ising: treatment with sevelamer was associated with a signiﬁcant
survival beneﬁt as compared to calcium-containing phosphate
binders in multivariate analyses in subjects new to hemodialysis
[11].
The predicted changes in EBT scores are also based on only
one clinical trial in 200 patients. The effect of 1 year of sevelamer
treatment is to change cardiovascular risk at that point. The only
presumption made about future effect is that the predictive
ability of the calciﬁcation score is not itself affected by treatment,
i.e., the impact of a change in score is correctly reﬂected by the
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respective failure-time curves. This type of assumption is com-
monly required when intermediate outcomes are used. Only
long-term data can demonstrate this conclusively.
The economic implications estimated in this study are con-
servative in that only acute inpatient costs are included for the
management of cardiovascular events. There were insufﬁcient
data to reliably estimate subsequent care costs in patients with
ESRD who are already receiving intense care. The consequences
in terms of fractures and vascular access problems are also not
included, further contributing to the conservative nature of the
estimates. Indeed, in a study comparing patients on sevelamer to
controls not receiving this binder, a 50% reduction was observed
in all-cause ﬁrst hospitalization over 17 months of follow-up
leading to an annual savings of more than $16,500 per patient,
on average [12].
In summary, randomized controlled trials have shown that
the use of sevelamer compared to calcium-based binders moder-
ates valvular and vascular calciﬁcation, predictors of cardiovas-
cular and all-cause mortality in ESRD. As long-term follow-up
data were not yet available, understanding the implications of
this physiological effect from a clinical and economic perspective
requires predictive equations. Development of such a model
cannot wait for the accumulation of follow-up data because
payers and policymakers must decide today whether or not to
reimburse for this binder, and individual physicians must make
treatment decisions based on the available evidence. Although
subject to the uncertainties inherent in modeling long-term out-
comes based on short-term clinical trial results, this Canadian
adaptation—which, like the original model, is based on the
assumption that coronary calciﬁcation is a serious problem exac-
erbated by exogenous calcium—suggests that use of sevelamer
should be considered an economically acceptable approach to
treating hyperphosphatemia in patients on hemodialysis.
Source of ﬁnancial support: This work was supported in part by a grant
from Genzyme Canada to Caro Research. Genzyme collaborated in
Table 1 Hospital length of stay and cost assumptions and characteristics of the patient population for the base case analysis
Model parameter
Hospitalization
(mean LOS in days; mean cost in 2005 CAD$)
Alive at discharge Died in hospital
LOS Cost LOS Cost
Congestive heart failure 9 9,199 12 18,961
Coronary artery disease 6 11,627 8 22,429
Cerebrovascular disease 10 12,370 12 18,524
Aortic disease 11 24,947 8 29,150
Peripheral arterial disease 9 13,280 16 25,005
Demographics Mean or % Interquartile range
Age (years) 54 40–67
Sex (males) 60%
Race (white) 85%
Smoking (smokers) 6%
Physiological parameters
Total-cholesterol (mmol/L) 4.75 3.95–5.50
HDL-cholesterol (mmol/L) 1.16 0.90–1.36
Diastolic blood pressure (mmHg)
Hypertension 85 74–95
No hypertension 73 64–81
Renal parameters
Serum phosphate (mmol/L) 1.84 1.52–2.15
Serum calcium (mmol/L) 2.34 2.25–2.44
Parathyroid hormone (pg/mL) 318 80–436
Vintage (months)
Diabetes 28 10–24
No diabetes 79 16–120
Comorbidities
Diabetes by age group
29 years 0%
30–49 years 2%
50–64 years 23%
65 years 18%
Hypertension by sex
Males 80%
Females 63%
CVD history by diabetes and age
Diabetes
29 years 0%
30–49 years 46%
50–64 years 73%
65 years 88%
No Diabetes
29 years 3%
30–49 years 11%
50–64 years 31%
65 years 58%
Treatment
Dose sevelamer (mg) 6,136 3,781–8,607
Dose calcium acetate (mg) 4,443 2,549–5,766
Dose calcium carbonate (mg) 3,470 2,651–4,323
Baseline EBT calciﬁcation score 1,500 79–1,652
LOS, length of stay; HDL, high-density lipoprotein; EBT, electron-beam tomography.
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helping set the speciﬁcations for the study but had no role in methodologi-
cal decisions or interpretation of results. They were also allowed to review
and comment on this manuscript but were explicitly forbidden from
exerting any editorial control.
References
1 London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial
interactions in end-stage renal disease. Kidney Int 1996;50:
600–8.
2 Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coro-
nary artery calcium score to predict coronary heart disease events:
a systematic review and meta-analysis. Arch Intern Med 2004;
164:1285–92.
3 Block GA. Prevalence and clinical consequences of elevated
Ca ¥ P product in hemodialysis patients. Clin Nephrol 2000;54:
318–24.
4 Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group:
sevelamer attenuates the progression of coronary and aortic cal-
ciﬁcation in hemodialysis patients. Kidney Int 2002;62:245–52.
5 Huybrechts KF, Caro JJ, Wilson DA, O’Brien JA. Health and
economic consequences of sevelamer use for hyperphosphatemia
in patients on hemodiálisis. Value Health 2005;8:549–61.
6 Huybrechts KF, Caro JJ, London GM. Modeling the implications
of changes in vascular calciﬁcation in patients on hemodialysis.
Kidney Int 2005;67:1532–8.
7 Blacher J, Guérin AP, Pannier B, et al. Arterial calciﬁcations,
arterial stiffness, and cardiovascular risk in end-stage renal
disease. Hypertension 2001;38:938–42.
8 Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiff-
ening and vascular calciﬁcations in end-stage renal disease.
Nephrol Dial Transplant 2000;15:1014–21.
9 Ontario Ministry of Health and Long-Term Care. Ontario Health
Insurance (OHIP) Schedule of Beneﬁts and Fees. Physician Ser-
vices Schedule of Beneﬁts, October 1, 2005.
10 Ontario Ministry of Health and Long-Term Care. Ontario drug
beneﬁt formulary/comparative drug index. Available from:
https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp
[Accessed April 14, 2006].
11 Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary
calciﬁcation and phosphate binder choice in incident hemodialy-
sis patients. Kidney Int 2007;71:438–41.
12 Collins AJ, St. Peter WL, Dalleska FW, et al. Hospitalization risks
between Renagel phosphate binder treated and non-Renagel
treated patients. Clin Nephrol 2000;54:334–41.
0 5,000 10,000 15,000 20,000 25,000 30,000 35,000
Incremental cost-effectiveness ratio 
(CAD$/discounted life-year gained)
Model time horizon (15 years, 5 years*)
Treatment effect: linear regression - EBT increase
(95% CI ß-coeff elemental calcium)
Treatment effect: logistic regression
(95% CI ß-coeff binder type)
CVD management cost (150%, 50%)
Treatment effect: CVD risk
(95% CI ß-coeff calcification score) 
Discount rate (0%, 5%)
Treatment cost (15% discount)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 2,500 5,000 7,500 10,000 12,500 15,000 17,500 20,000 22,500
Value of the ceiling ratio (CAD$)
P
ro
b
ab
ili
ty
 C
o
st
-E
ff
ec
ti
ve
CER ($/dLYG) CER ($/LYG)
Panel B 
Panel A 
Figure 2 Panel A: Univariate sensitivity analyses.
The solid vertical line represents the base case
incremental cost-effectiveness of sevelamer versus
calcium carbonate. Horizontal bars indicate range
obtained for each variable (*: shorter time hori-
zons are not depicted for clarity. Two years:
CAD$88,767/dLYG). Panel B: Cost-Effectiveness
Acceptability Curve, derived by simultaneously
varying the treatment effect [95% conﬁdence inter-
val (CI) for the b-coefﬁcients in: 1) logistic regres-
sion providing the probability a patient will have an
increase in calciﬁcation score; 2) linear regression
predicting the magnitude of the increase in calciﬁ-
cation score; 3) Cox-proportional hazards regres-
sion predicting cardiovascular risk] and the
cardiovascular disease (CVD) management cost
(50%). EBT, electron-beam tomography.
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